The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.
 
Phillip Lee Palmbos
No Relationships to Disclose
 
Felix Yi-Chung Feng
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Celgene; GenomeDx; Medivation/Astellas
Research Funding - Celgene (Inst); Medivation/Astellas (Inst); Varian Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - Patent not licensed to any company (Inst)
 
Scott A. Tomlins
Honoraria - Roche; Ventana Medical Systems
Consulting or Advisory Role - Ventana Medical Systems
 
William Kevin Kelly
Consulting or Advisory Role - Sanofi
Research Funding - Novartis (Inst); Sanofi (Inst)
Other Relationship - Sanofi
 
Alicia Katherine Morgans
Consulting or Advisory Role - Myriad Genetics
Travel, Accommodations, Expenses - Myriad Genetics
 
Mary-Ellen Taplin
Honoraria - Bayer; Dendreon; Janssen-Ortho; Medivation; Tokai Pharmaceuticals
Consulting or Advisory Role - Bayer; Best Doctors, Inc; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen-Ortho; Medivation; Sanofi; Tokai Pharmaceuticals; UpToDate
Research Funding - Bayer; Genentech; Janssen-Ortho; Medivation
Travel, Accommodations, Expenses - Dendreon; Janssen Oncology; Medivation; Tokai Pharmaceuticals
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
Other Relationship - Exelixis; Medivation; Takeda
 
Emmanuel S. Antonarakis
Honoraria - Dendreon; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Dendreon; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Przemyslaw Twardowski
Honoraria - Janssen
 
Jon Jacobson
No Relationships to Disclose
 
Matthew S. Davenport
No Relationships to Disclose
 
Stephanie Daignault
Consulting or Advisory Role - Augmenix
Research Funding - Pfizer (Inst)
 
Karen E. Knudsen
Consulting or Advisory Role - Celgene; CellCentric
Research Funding - Celgene (Inst)
 
Maha Hussain
Consulting or Advisory Role - Johnson & Johnson; Synthon
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pa; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,7